Trial Profile
ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs CEP 11981 (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ERICA
- 18 Sep 2023 Status changed from active, no longer recruiting to discontinued.
- 08 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2020 Status changed from suspended to recruiting.